Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)
China
· Delayed Price · Currency is CNY 54.76
+0.34 (0.62%)
Apr 29, 2026, 3:00 PM CST
Hangzhou Alltest Biotech Revenue
Hangzhou Alltest Biotech had revenue of 195.37M CNY in the quarter ending March 31, 2026, a decrease of -6.29%. This brings the company's revenue in the last twelve months to 892.24M, up 1.95% year-over-year. In the year 2025, Hangzhou Alltest Biotech had annual revenue of 905.34M with 4.47% growth.
Revenue (ttm)
892.24M
Revenue Growth
+1.95%
P/S Ratio
4.72
Revenue / Employee
926.93K
Employees
960
Market Cap
4.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 905.34M | 38.76M | 4.47% |
| Dec 31, 2024 | 866.58M | 111.89M | 14.83% |
| Dec 31, 2023 | 754.70M | -2.63B | -77.73% |
| Dec 31, 2022 | 3.39B | 1.52B | 80.88% |
| Dec 31, 2021 | 1.87B | 737.87M | 64.98% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Gongdong Medical Technology | 1.16B |
| Well Lead Medical | 1.64B |
| Caina Technology | 341.55M |
| Shanghai Kindly Enterprise Development Group Co.,LTD. | 2.30B |
| SWS Hemodialysis Care | 806.82M |
| Chimin Health Management | 637.78M |
| Beijing Centergate Technologies (holding) | 2.30B |
| Jiangxi Sanxin Medtec | 1.69B |